A comprehensive study of the association between drug hepatotoxicity and daily dose, liver metabolism, and lipophilicity using 975 oral medications

Zuquan Weng1,*, Kejian Wang1,*, Haibo Li2, Qiang Shi1

1 Division of Systems Biology, National Center for Toxicological Research, Food and Drug Administration, Jefferson, AR 72079, USA
2 Department of Clinical Laboratory Medicine, Nantong Maternal and Child Health Hospital, Nantong, Jiangsu, 226018, China

*These authors have contributed equally to this work

Correspondence to: Qiang Shi, e-mail: qiang.shi@fda.hhs.gov

Keywords: Pathology Section, hepatotoxicity, metabolism, lipophilicity, dose, oral

Received: June 05, 2015 Accepted: June 13, 2015 Published: June 24, 2015

ABSTRACT

It was recently suggested that daily dose, liver metabolism and lipophilicity were associated with an oral drug’s potential to cause hepatotoxicity, but this has not been widely accepted. A likely reason is that published data lack comprehensiveness, as they were based on only about one third of all FDA approved single-active-ingredient oral prescription drugs. Here the 975 oral drugs used worldwide which have a Defined Daily Dose (DDD) designated in the World Health Organization’s Anatomical Therapeutic Chemical classification system and whose hADRs potential and metabolism data are available in the Micromedex Drugdex® compendium were studied, with their lipophilicity calculated by the partition coefficient LogP. Of the 975 drugs examined, 49% (478) have the potential to induce at least one type of hepatic adverse drug reactions (hADRs) such as fatal hepatotoxicity, acute liver failure, significant ALT/AST elevation, hepatitis, and jaundice. By single factor analysis, a higher DDD (≥100 mg) was found to be associated with all types of hADRs, and extensive liver metabolism (≥50%) was associated with a subset of hADRs including fatal hADRs, hepatitis, and jaundice, while LogP showed no relation to any types of hADRs. Contrary to previous reports, none of the combination, neither DDD and liver metabolism, nor DDD and LogP, was found to be more predictive of hADRs than using DDD or liver metabolism alone. These data provide convincing evidence that a higher daily dose and extensive liver metabolism, but not lipophilicity, are independent but not synergistic risk factors for oral drugs to induce hepatotoxicity.

INTRODUCTION

Drug hepatotoxicity is the leading cause of acute liver failure and unfavorable regulatory actions such as drug non-approvals or market withdrawals. Tremendous efforts have been undertaken to predict which drug is more likely than the others to induce hepatic adverse drug reactions (hADRs), but relatively little progress has been made [1]. Inspired by the observation that drugs received unfavorable regulatory actions due to liver injury are very often administrated at high doses [2, 3], a recent study examined 230 mostly prescribed U.S. drugs and concluded that a higher dose (that is, ≥50 mg) is a risk factor for severe hADRs induced by oral medications [4]. Using a slightly smaller number of 207 drugs, the same group later on reported that extensive liver metabolism (that is, ≥50% liver metabolism) is another risk factor for an oral drug to induce hADRs, and the combination of daily dose and liver metabolism appears to be synergistic in predicting liver risks [5]. More recently, based on data from 164 drugs, another group reported that the combination of oral dose and lipophilicity was remarkably more effective than either alone in predicting a drug’s hADR potential [6]. However, this combination appeared ineffective in a larger
number of 254 drugs [7]. The general belief remains that none of these medication characteristics are able to predict hADRs with high confidence [1]. An outstanding caveat is that all previous studies lack comprehensiveness, that is, the number of drugs examined is relatively small as compared to all FDA approved new molecular entities (NMEs) or currently used oral prescription drugs.

According to a recent report, the FDA has approved 1,453 new molecular entities from the year 1827 to 2013 [8]. However, this is an underestimate by about 10%. According to the FDA official statistics, 1,527 NMEs were approved by the FDA during the period of 1940 to 2011 (http://www.fda.gov/AboutFDA/WhatWeDo/History/ProductRegulation/SummaryofNDAApprovalsReceipts1938tothepresent/default.htm). In the year 2012 to 2014, the FDA has approved an additional 107 NMEs (http://www.fda.gov/Drugs/DevelopmentApprovalProcess/DrugInnovation/default.htm). Therefore at least a total of 1,634 NMEs has been approved by the FDA. Though some approved drugs were later on discontinued or withdrawn from the market [9, 10], the number of currently used single-active-ingredient oral prescription drugs, as downloaded in June 2014 from the FDA Online Label Repository using the FDALabel database [11], is 736. This raised the possibility that previous reports on dose, metabolism and lipophilicity affecting hADRs could be biased, as only a small fraction of drugs, that is, only around 15% of all the FDA approved NMEs or 34% of all currently used U.S. oral prescription drugs, were included for analysis. The present study aimed at to scrutinize the role of dose, metabolism and lipophilicity, each alone or in combination, in predicting an oral drug’s hADR potential using a comprehensive list of drugs covering nearly all human oral medications.

RESULTS

As of July 2013, the WHO ATC/DDD system contains 5,015 drug records (Supplementary Table 1), with 2,338 drugs having DDDs assigned (Supplementary Table 2), among which 1,013 drugs are used only by oral administration and 379 drugs are used both orally and non-orally (Supplementary Table 3). Of the 1,392 drugs that can be used by oral route, 975 drugs (Supplementary Table 4) were found to be included in the Micromedex Drugdex® compendium and therefore were chosen for further analysis.

Of the 975 drugs analyzed, 478 (49%) drugs were found to be associated with at least one type of hADRs. Specifically, 150, 208, 37, 309, 251, 61, and 291 drugs were shown to have the potential to induce fatal hADRs, liver failure, liver transplantation, jaundice, biomarker increase, hepatomegaly and hepatitis, respectively (Supplementary Table 4). Interestingly, though a previous report using 230 mostly prescribed U.S. drugs found no drugs causing liver transplantation when their daily doses were equal or less than 10 mg [4], here we found that ramipril with a DDD of 2.5 mg is associated with liver transplantation.

The Cochran-Armitage trend test was used to examine if DDDs or LogP are associated with a drug’s hADR potential. Table 1 shows that the percentage of drugs inducing all major types of hADRs was significantly increased when DDDs became higher. Specifically, among the 169 drugs whose DDDs are less than 10 mg, only 12 drugs (7%) can cause fatal hADRs. However, among the 288 drugs whose DDDs are in the range of 10 to 100 mg, 35 drugs (12%) can induce fatal hADRs. As for the 518 drugs whose DDDs are equal or large than 100 mg, 103 drugs (20%) can trigger fatal hADRs. The difference

| Table 1: Association between Defined Daily Dose and hepatic adverse drug reactions |
|--------------------------------------|-------------------------------|-------------------------------|-------------------------------|------------------|
| hADRs Type                          | DDD < 10 mg (n = 169)         | 10 ≤ DDD < 100 mg (n = 288)   | DDD ≥ 100 mg (n = 518)       | P-value          |
| Fatal hADRs                         | 12 (7%)                       | 35 (12%)                      | 103 (20%)                    | 1.31E-05***      |
| Liver Failure                       | 13 (8%)                       | 58 (20%)                      | 137 (26%)                    | 3.42E-07***      |
| Liver Transplantation               | 1 (1%)                        | 8 (3%)                        | 28 (5%)                      | 2.41E-03**       |
| Jaundice                            | 36 (21%)                      | 83 (29%)                      | 190 (37%)                    | 8.43E-05***      |
| Biomarker Increase                  | 23 (14%)                      | 67 (23%)                      | 161 (31%)                    | 3.43E-06***      |
| Hepatomegaly                        | 6 (4%)                        | 12 (4%)                       | 43 (8%)                      | 8.29E-03**       |
| Hepatitis                           | 27 (16%)                      | 74 (26%)                      | 190 (37%)                    | 5.94E-08***      |
| Severe hADRs                        | 16 (9%)                       | 60 (21%)                      | 149 (29%)                    | 1.53E-07***      |
| All hADRs                           | 60 (36%)                      | 130 (45%)                     | 288 (56%)                    | 1.60E-06***      |

P value was determined using the Cochran-Armitage test. *P < 0.05; **P < 0.01; ***P < 0.001
among dose groups was statistically significant ($p < 0.001$).

Similar results were obtained regarding other types of hADRs including liver failure, liver transplantation, jaundice, biomarker increase, hepatomegaly, and hepatitis, either individually or combined together. In contrast, Table 2 shows the percentage of drugs inducing different types of hADRs (except for jaundice) was not associated with LogP ($p > 0.05$).

The Fisher’s exact test was used to determine if extensive liver metabolism, that is, ≥50% of liver metabolism as defined in a previous report [5], is associated with a drug’s hADR potential. As shown in Table 3, among the 483 drugs that are subjected to extensive liver metabolism, 99 drugs (20%) can cause fatal hADRs, while only 18 out of 162 (11%) drugs that do not undergo extensive liver metabolism can induce fatal hADRs. Such difference was statistically significant ($p < 0.01$). Similarly, extensive liver metabolism was also associated with jaundice, but not the remaining individual types of hADRs. Nevertheless, the pooled hADRs were indeed significantly associated with extensive liver metabolism ($p < 0.01$). In contrast to the data in Table 1, none of the statistically significant association reached the confidence level of $p < 0.001$ in Table 3.

Table 2: Association between LogP and hepatic adverse drug reactions

| hADR Type       | LogP < 1 ($n = 214$) | 1 ≤ LogP < 3 ($n = 378$) | LogP ≥ 3 ($n = 360$) | P-value  |
|-----------------|----------------------|--------------------------|----------------------|----------|
| Fatal hADRs     | 35 (16%)             | 46 (12%)                 | 68 (19%)             | 2.35E-01 |
| Liver Failure   | 55 (26%)             | 64 (17%)                 | 88 (24%)             | 8.97E-01 |
| Liver Transplantation | 9 (4%)       | 8 (2%)                   | 20 (6%)              | 2.41E-01 |
| Jaundice        | 69 (32%)             | 98 (26%)                 | 141 (39%)            | 2.43E-02'|
| Biomarker Increase | 54 (25%)       | 94 (25%)                 | 101 (28%)            | 3.94E-01 |
| Hepatomegaly    | 19 (9%)              | 23 (6%)                  | 19 (5%)              | 1.04E-01 |
| Hepatitis       | 68 (32%)             | 107 (28%)                | 115 (32%)            | 8.15E-01 |
| Severe hADRs    | 58 (27%)             | 72 (19%)                 | 94 (26%)             | 8.69E-01 |
| All hADRs       | 105 (49%)            | 177 (47%)                | 192 (53%)            | 2.23E-01 |

P value was determined using the Cochran-Armitage test. *$P < 0.05$; **$P < 0.01$; ***$P < 0.001$

The comparison between using liver metabolism alone and its combination with LogP or DDD, as well as those using LogP alone and its combination with liver metabolism or DDD, also showed a similar tendency, that is, no added value was obtained when combining two factors, as compared to using either alone. Detailed results were presented in the Supplementary Table 5.

To further clarify the possible interactions among DDD, liver metabolism and LogP, the multivariate logistic regression analysis was performed. As shown in Table 5, no statistically significant interactions between DDD and LogP, or DDD and metabolism, were observed in predicting all the hADRs types examined ($p > 0.01$). Similar results were obtained in analyzing the possible interaction between LogP and metabolism (data not shown). These results demonstrate that DDD, live metabolism, and LogP do not interact with each other in predicting a drug’s hADR potential.

As previous reports used either 50 mg [4] or 100 mg [6] as a cutoff for daily dose, additional analysis was performed using 50 mg as a cutoff to facilitate a more direct comparison between our dataset and those published. Nearly identical results were obtained in these additional analyses (data not shown).
DISCUSSION

This is the most comprehensive study so far that aimed at examining the relation between a drug’s hADR potential and its daily dose, liver metabolism, or lipophilicity. Our results not only consolidated and but also remarkably expanded the view that a higher daily dose is a risk factor for oral drugs to induce hADRs. Though a previous report based on 230 drugs failed to demonstrate a statistically significant association between daily dose and ALT > 3 × ULN, nor daily dose and jaundice [4], here these associations became clearly established by using a more than 4-fold larger number of drugs. Additionally, daily dose was found to be strongly associated with hepatitis and hepatomegaly, two types of hADRs that were not examined in the previous study [4]. This finding is of particular significance because nearly one third (291 out of 975) of drugs were found to be associated with hepatitis. Our data provide convincing evidence that a higher daily dose is a risk factor for all major types of hADRs induced by oral medications.

In partial agreement with a previous study [5], we found that only a subset of hADRs was associated with extensive liver metabolism. It is notable that both our study and the previous report [5] showed that fatal DILI and ALT > 3 × ULN, nor daily dose and jaundice [4], here these associations became clearly established by using a more than 4-fold larger number of drugs. Additionally, daily dose was found to be strongly associated with hepatitis and hepatomegaly, two types of hADRs that were not examined in the previous study [4]. This finding is of particular significance because nearly one third (291 out of 975) of drugs were found to be associated with hepatitis. Our data provide convincing evidence that a higher daily dose is a risk factor for all major types of hADRs induced by oral medications.

In partial agreement with a previous study [5], we found that only a subset of hADRs was associated with extensive liver metabolism. It is notable that both our study and the previous report [5] showed that fatal DILI and ALT > 3 × ULN, nor daily dose and jaundice [4], here these associations became clearly established by using a more than 4-fold larger number of drugs. Additionally, daily dose was found to be strongly associated with hepatitis and hepatomegaly, two types of hADRs that were not examined in the previous study [4]. This finding is of particular significance because nearly one third (291 out of 975) of drugs were found to be associated with hepatitis. Our data provide convincing evidence that a higher daily dose is a risk factor for all major types of hADRs induced by oral medications.

Another interesting finding is that when lipophilicity was combined with DDD, no added value was obtained. This is in contrast to a recent report which showed that a combination of LogP ≥ 3 and DDD ≥ 100 mg was remarkable more predictive of a drug’s hADR potential than using either criterion alone [6], but is consistent with a more recent publication that was based on a slightly large number of drugs [7]. It seems apparent that lipophilicity, either alone or in combination with other factors, does not play a significant role in predicting an oral drug’s liver risks.

Our study provides a unique quantitative estimate of the hADR risks in overall human medication use, that is, 49% of the drugs examined have the potential to induce...
Table 4: Predicting hepatic adverse drug reactions using the combination of Defined Daily Dose, liver metabolism or LogP

| Criteria | hADRs | OR (95% CI) | TPR | FPR |
|----------|-------|-------------|-----|-----|
| **Fatal hADRs** | | | |
| DDD ≥ 100 mg | Y | 103 | 415 | 2.17*** (1.47–3.21) | 69% | 50% |
| | N | 47 | 410 | | | |
| DDD ≥ 100 mg & LogP ≥ 3 | Y | 44 | 117 | 2.46*** (1.60–3.73) | 30% | 15% |
| | N | 105 | 686 | | | |
| DDD ≥ 100 mg & LM ≥ 50% | Y | 66 | 171 | 2.70*** (1.76–4.15) | 56% | 32% |
| | N | 51 | 357 | | | |
| **Liver Failure** | | | |
| DDD ≥ 100 mg | Y | 137 | 381 | 1.95*** (1.40–2.73) | 66% | 50% |
| | N | 71 | 386 | | | |
| DDD ≥ 100 mg & LogP ≥ 3 | Y | 55 | 106 | 2.18*** (1.47–3.20) | 27% | 14% |
| | N | 152 | 639 | | | |
| DDD ≥ 100 mg & LM ≥ 50% | Y | 75 | 162 | 1.76** (1.20–2.57) | 47% | 33% |
| | N | 85 | 323 | | | |
| **Liver Transplantation** | | | |
| DDD ≥ 100 mg | Y | 28 | 490 | 2.84** (1.28–6.92) | 76% | 52% |
| | N | 9 | 448 | | | |
| DDD ≥ 100 mg & LogP ≥ 3 | Y | 15 | 146 | 3.59*** (1.69–7.43) | 41% | 16% |
| | N | 22 | 769 | | | |
| DDD ≥ 100 mg & LM ≥ 50% | Y | 13 | 224 | 1.76 (0.74–4.20) | 50% | 36% |
| | N | 13 | 395 | | | |
| **Jaundice** | | | |
| DDD ≥ 100 mg | Y | 190 | 328 | 1.65*** (1.24–2.19) | 61% | 49% |
| | N | 119 | 338 | | | |
| DDD ≥ 100 mg & LogP ≥ 3 | Y | 79 | 82 | 2.36*** (1.65–3.39) | 26% | 13% |
| | N | 229 | 562 | | | |
| DDD ≥ 100 mg & LM ≥ 50% | Y | 117 | 120 | 2.29*** (1.62–3.23) | 49% | 30% |
| | N | 122 | 286 | | | |
| **Biomarker Increase** | | | |
| DDD ≥ 100 mg | Y | 161 | 357 | 1.84*** (1.35–2.50) | 64% | 49% |
| | N | 90 | 367 | | | |
| DDD ≥ 100 mg & LogP ≥ 3 | Y | 61 | 100 | 1.96*** (1.34–2.84) | 24% | 14% |
| | N | 188 | 603 | | | |
| DDD ≥ 100 mg & LM ≥ 50% | Y | 98 | 139 | 2.01*** (1.41–2.86) | 48% | 32% |
| | N | 106 | 302 | | | |
at least one type of hADRs. This result may help health care providers, regulators and pharmaceutical industries better evaluate the risks of hADRs associated with drugs.

Due to the relatively rareness of severe hADRs and ethical issues, many theories are difficult to be tested experimentally and are therefore highly speculative at this time, and controversies are not uncommon in this field [13]. Given that few general rules have been established in the past decades, any new rules such as the one dubbed “rule of 2” [6] shall be treated with caution. Similar caution and scrutiny should be exercised in viewing the recently developed new experimental approaches aimed at predicting hADRs, such as those using high-content analysis of cellular injury [14], mitochondrial dysfunctions [15] and a combination of mechanistic toxicity endpoints [16], as all these studies were also based upon drugs in the low hundreds. To minimize further confusions, our study highlights the importance of avoiding overgeneralization before comprehensive studies are in place. By the same token, the present study has two apparent limitations. First, the drug list does not cover all drugs used by human kind. Secondly, understandings of a drug’s hADRs potential, as well as its metabolism, are evolving with time and the present study represents only a snapshot of current knowledge deposited in a single database, the Micromedex Drugdex® compendium. Our findings need to be further evaluated when more data become available and new drugs come to the market in the future.

| Criteria                  | hADRs | OR (95% CI) | TPR | FPR |
|---------------------------|-------|-------------|-----|-----|
|                           | Y     | N           |     |     |
| Hepatomegaly              |       |             |     |     |
| DDD ≥ 100 mg              | Y     | 43          | 475 | 2.21** (1.22–4.13) | 70% | 52% |
|                           | N     | 18          | 439 |     |     |     |
| DDD ≥ 100 mg & LogP ≥ 3  | Y     | 16          | 145 | 1.83 (0.94–3.41) | 26% | 16% |
|                           | N     | 45          | 746 |     |     |     |
| DDD ≥ 100 mg & LM ≥ 50%  | Y     | 23          | 214 | 1.80 (0.94–3.44) | 50% | 36% |
|                           | N     | 23          | 385 |     |     |     |
| Hepatitis                 |       |             |     |     |
| DDD ≥ 100 mg              | Y     | 190         | 328 | 2.04*** (1.52–2.74) | 65% | 48% |
|                           | N     | 101         | 356 |     |     |     |
| DDD ≥ 100 mg & LogP ≥ 3  | Y     | 71          | 90  | 2.06*** (1.43–2.96) | 24% | 14% |
|                           | N     | 219         | 572 |     |     |     |
| DDD ≥ 100 mg & LM ≥ 50%  | Y     | 108         | 129 | 2.58*** (1.81–3.68) | 52% | 30% |
|                           | N     | 100         | 308 |     |     |     |
| Severe hADRs              |       |             |     |     |
| DDD ≥ 100 mg              | Y     | 149         | 369 | 2.02*** (1.47–2.80) | 66% | 49% |
|                           | N     | 76          | 381 |     |     |     |
| DDD ≥ 100 mg & LogP ≥ 3  | Y     | 57          | 104 | 2.05*** (1.39–2.99) | 25% | 14% |
|                           | N     | 167         | 624 |     |     |     |
| DDD ≥ 100 mg & LM ≥ 50%  | Y     | 83          | 154 | 1.93*** (1.33–2.80) | 48% | 33% |
|                           | N     | 89          | 319 |     |     |     |
| All hADRs                 |       |             |     |     |
| DDD ≥ 100 mg              | Y     | 288         | 230 | 1.76*** (1.35–2.29) | 60% | 46% |
|                           | N     | 190         | 267 |     |     |     |
| DDD ≥ 100 mg & LogP ≥ 3  | Y     | 102         | 59  | 1.95*** (1.35–2.81) | 22% | 12% |
|                           | N     | 372         | 419 |     |     |     |
| DDD ≥ 100 mg & LM ≥ 50%  | Y     | 157         | 80  | 2.19*** (1.55–3.09) | 45% | 27% |
|                           | N     | 193         | 215 |     |     |     |

*P value was determined using the Fisher’s exact test. Y, positive; N, negative; DDD, Defined Daily Dose; OR, odds ratio; CI, confidence interval; LM, liver metabolism; TPR, true positive rate; FPR, false positive rate. 

*P < 0.05; **P < 0.01; ***P < 0.001
MATERIALS AND METHODS

All drug records in the World Health Organization’s (WHO) Anatomical Therapeutic Chemical classification and Defined Daily Dose (ATC/DDD) system were manually collected from the official website at http://www.whocc.no/atc_ddd_index/ in July 2013. Only drugs with an assigned DDD were selected for further analysis. Though previous reports [4, 6, 7] used other sources than the WHO ATC/DDD system to determine a drug’s daily dose, we chose not to do so. This not only minimizes subjectivity but also reduces possible errors, as the WHO ATC/DDD system represents the consensus achieved among worldwide experts and has been considered as a reliable information source for nearly 30 years. Notably, the WHO ATC/DDD system also updates the DDDs when the dosage changes over time (http://www.whocc.no/filearchive/publications/2014_guidelines.pdf).

If a drug is used by both oral and non-oral routes of administration, it was also included in the present study, but only the oral DDD was used for analysis. For a small number of oral drugs that are used for multiple diseases and therefore have multiple DDDs, the average DDDs were used.

In line with previous reports [4, 5], the Micromedex Drugdex® compendium was used to collect the drug metabolism data and to determine if a drug causes any types of hADRs. For data collection, the criteria used in previous reports [4, 5] were used with slight modifications. These modifications include (1) though previous reports focused on “alanine aminotransferase (ALT) greater than 3 times the upper limit of normal” (ALT > 3 × ULN) as one important type of hADRs [4, 5], we used a more general term, that is, biomarker increase, to cover this type of hADRs, for which we included not only ALT > 3 × ULN, but also other findings such as “clinically significant increase of ALT and/or aspartate aminotransferase (AST)”, or “ALT/AST elevations that led to drug withdrawal”, (2) we additionally collected drugs that are associated with hepatitis and/or hepatomegaly, as we noticed that lots of drugs can cause these types of hADRs, (3) we used the term “severe hADRs” to cover hADRs leading to death or causing acute liver failure or necessitating liver transplantation. Other criteria are the same as previous reports [4, 5]. As the Micromedex Drugdex® compendium is updating constantly, and our data collection was completed in March 2014, updates after that will not be reflected in the present manuscript.

In line with a previous report, drug lipophilicity was determined by the partition coefficient LogP [6], which was calculated using the online software ALOGPS 2.1 (http://www.vcclab.org/lab/alogsps/start.html).

Statistical analysis: For single factor analysis, the Cochran-Armitage test was used to determine the statistical significance of the association between DDDs and hADRs, and the Fisher’s exact test was used for liver metabolism and hADRs. The possible interaction between DDD and LogP or liver metabolism, or LogP and liver metabolism, was determined by multivariate logistic regression model using the Wald test. A p value less than 0.05, 0.01 or 0.001 was considered as statistically meaningful.

Table 5: Interactions between oral dose and LogP, or oral dose and hepatic metabolism analyzed by logistic regression

|                      | Oral Dose × LogP | Oral Dose × Hepatic Metabolism |
|----------------------|-----------------|------------------------------|
|                      | Adjusted OR     | 95% CI                     | P-value | Adjusted OR | 95% CI | P-value |
| Fatal hADRs          | 1.31            | 0.62–2.77                  | 0.484   | 2.14        | 0.69–6.66 | 0.190 |
| Liver Failure         | 1.44            | 0.75–2.78                  | 0.270   | 1.12        | 0.45–2.8  | 0.800 |
| Liver Transplantation | 1.58            | 0.34–7.34                  | 0.557   | 0.00        | 0.00–+∞   | 0.986 |
| Jaundice             | 1.26            | 0.72–2.23                  | 0.419   | 1.19        | 0.51–2.77 | 0.687 |
| Biomarker Increase    | 1.44            | 0.78–2.66                  | 0.240   | 1.32        | 0.56–3.1  | 0.532 |
| Hepatomegaly         | 5.17            | 1.26–21.22                 | 0.022*  | 2.79        | 0.69–11.25 | 0.149 |
| Hepatitis            | 1.48            | 0.82–2.67                  | 0.188   | 2.68        | 1.17–6.16 | 0.020* |
| Severe hADRs         | 1.17            | 0.62–2.22                  | 0.627   | 1.16        | 0.47–2.86 | 0.755 |
| All hADRs            | 1.15            | 0.67–1.97                  | 0.610   | 1.40        | 0.66–2.95 | 0.382 |

The Wald test was used to determine the statistical significance of interacting variable in logistic regression. OR, odds ratio; CI, confidence interval. *P < 0.05; **P < 0.01; ***P < 0.001
CONFLICTS OF INTEREST

Nothing to report.

FINANCIAL SUPPORT

This project is supported by the U.S. FDA’s Office of Women’s Health. Drs. Zuquan Weng and Kejian Wang are supported by the Research Participation Program at the National Center for Toxicological Research administrated by the Oak Ridge Institute for Science and Education through an interagency agreement between the U.S. Department of Energy and the U.S. FDA. Dr. Haibo Li is supported by the International Cooperation and Exchanges (2012) program from the Department of Health in Jiangsu Province, China.

Author’s contributions

Zuquan Weng and Haibo Li collected the data; Kejian Wang analyzed the data; Qiang Shi designed the whole study. All authors were involved in the interpretation of the data and development of manuscript.

Disclaimer

The information in these materials is not a formal dissemination of information by FDA and does not represent agency position or policy.

Editorial note

This paper has been accepted based in part on peer-review conducted by another journal and the authors’ response and revisions as well as expedited peer-review in Oncotarget.

Abbreviations

hADRs, hepatic adverse drug reactions; DDD, Defined Daily Dose; NMEs, new molecular entities; FDA, Food and Drug Administration; WHO, World Health Organization; ATC/DDD, Anatomical Therapeutic Chemical classification and Defined Daily Dose system; ALT, alanine aminotransferase; AST, aspartate aminotransferase.

REFERENCES

1. Fontana RJ. Pathogenesis of idiosyncratic drug-induced liver injury and clinical perspectives. Gastroenterology. 2014; 146:914–928.

2. Uetrecht J. Idiosyncratic drug reactions: current understanding. Annual review of pharmacology and toxicology. 2007; 47:513–539.

3. Walgren JL, Mitchell MD, Thompson DC. Role of metabolism in drug-induced idiosyncratic hepatotoxicity. Critical reviews in toxicology. 2005; 35:325–361.

4. Lammert C, Einarsson S, Saha C, Niklasson A, Bjornsson E, Chalasani N. Relationship between daily dose of oral medications and idiosyncratic drug-induced liver injury: search for signals. Hepatology. 2008; 47:2003–2009.

5. Lammert C, Bjornsson E, Niklasson A, Chalasani N. Oral medications with significant hepatic metabolism at higher risk for hepatic adverse events. Hepatology. 2010; 51:615–620.

6. Chen M, Borlak J, Tong W. High lipophilicity and high daily dose of oral medications are associated with significant risk for drug-induced liver injury. Hepatology. 2013; 58:388–396.

7. Yu K, Geng X, Chen M, Zhang J, Wang B, Ilic K, Tong W. High daily dose and being a substrate of cytochrome P450 enzymes are two important predictors of drug-induced liver injury. Drug metabolism and disposition: the biological fate of chemicals. 2014; 42:744–750.

8. Kinch MS, Haynesworth A, Kinch SL, Hoyer D. An overview of FDA-approved new molecular entities: 1827-2013. Drug discovery today. 2014.

9. Issa AM, Phillips KA, Van Bebber S, Nidamarthy HG, Lasser KE, Haas JS, Alldridge BK, Wachter RM, Bates DW. Drug withdrawals in the United States: a systematic review of the evidence and analysis of trends. Current drug safety. 2007; 2:177–185.

10. Lasser KE, Allen PD, Woolhandler SJ, Himmelstein DU, Wolfe SM, Bor DH. Timing of new black box warnings and withdrawals for prescription medications. JAMA: the journal of the American Medical Association. 2002; 287:2215–2220.

11. Li H, Shi Q. Drugs and Diseases Interacting with Cigarette Smoking in US Prescription Drug Labelling. Clinical pharmacokinetics. 2015; 54:493–501.

12. Leung L, Kalgotkar AS, Obach RS. Metabolic activation in drug-induced liver injury. Drug metabolism reviews. 2012; 44:18–33.

13. Corsini A, Ganey P, Ju C, Kaplowitz N, Pessayre D, Roth R, Watkins PB, Albassam M, Liu B, Stancic S, Suter L, Bortolini M. Current challenges and controversies in drug-induced liver injury. Drug safety : an international journal of medical toxicology and drug experience. 2012; 35:1099–1117.

14. Xu JJ, Henstock PV, Dunn MC, Smith AR, Chabot JR, de Graaf D. Cellular imaging predictions of clinical drug-induced liver injury. Toxicological sciences : an official journal of the Society of Toxicology. 2008; 105:97–105.

15. Porceddu M, Buron N, Roussel C, Labbe G, Fromenty B, Borgne-Sanchez A. Prediction of liver injury induced by chemicals in human with a multiparametric assay on isolated mouse liver mitochondria. Toxicological sciences : an official journal of the Society of Toxicology. 2012; 129:332–345.

16. Aleo MD, Luo Y, Swiss R, Bonin PD, Potter DM, Will Y. Human drug-induced liver injury severity is highly associated to dual inhibition of liver mitochondrial function and bile salt export pump. Hepatology. 2014; 60:1015–22.